RxDoctor Payments Data

Imran Bawaney, MD

Cardiovascular Disease · Orlando, FLNPI 1396948980

Payments from drug & device makers

$519in general payments, 2019–2025

Across 10 payments — averaging $51.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$175
  • Pfizer$134
  • Medtronic$100
  • Novartis$75
  • Boston Scientific$20
  • AstraZeneca$14

What the payments were for

  • Food & beverage$50597%
  • Education$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$519 in reported general payments places this provider in the 15th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$190,848
Medicare patients
1,112
Services billed
2,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban231$247,149
EntrestoSacubitril/Valsartan45$56,758
Repatha SureclickEvolocumab58$46,264
XareltoRivaroxaban29$30,908
BrilintaTicagrelor24$20,495
LivaloPitavastatin Calcium17$8,003
Metoprolol Succinate247$3,053
Ranolazine ErRanolazine15$1,760
Rosuvastatin Calcium118$1,614
Atorvastatin Calcium131$1,586
Midodrine Hcl11$1,396
Metoprolol Tartrate149$1,325
Bisoprolol Fumarate35$1,234
Hydralazine Hcl63$1,073
ClopidogrelClopidogrel Bisulfate103$1,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$134$247,149231 claims
NovartisEntresto$75$56,75845 claims
AstraZenecaBrilinta$14$20,49524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →